Quantitative analysis for Insight Molecular Diagnostics Inc. (IMDX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (37.0) (grade D). 30 signals analyzed (25 differentiated alt-data).
IMDX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $4.36 | $3.87 | $4.20 |
| 2026-05-08 | $5.10 | $4.55 | $5.01 |
| 2026-05-20 | $6.21 | $5.55 | $6.19 |
| 2026-06-02 | $6.30 | $5.67 | $5.95 |
| 2026-06-12 | $5.71 | $5.33 | $5.61 |
| 2026-06-25 | $5.69 | $5.45 | $5.59 |
| 2026-07-08 | $5.11 | $4.57 | $4.79 |
| 2026-07-20 | $4.88 | $4.65 | $4.84 |
| 2026-07-30 | $4.66 | $4.41 | $4.60 |
| 2026-08-12 | $4.50 | $4.15 | $4.50 |
| 2026-08-24 | $4.46 | $4.23 | $4.32 |
| 2026-09-03 | $4.22 | $3.85 | $4.12 |
How Insight Molecular Diagnostics Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| UNCY | Unicycive Therapeutics, Inc. | $166M | — |
| PLYX | Polaryx Therapeutics, Inc. Common Stock | $160M | — |
| ORMP | Oramed Pharmaceuticals Inc. | $173M | — |
| APYX | Apyx Medical Corporation | $159M | — |
View all Health Care stocks by valuation and signals →
Insight Molecular Diagnostics Inc. (IMDX) scores Sell (37.0), and the composite conceals a 71-point disagreement between its dimensions. It is strongest on competitive moat at 91, and weakest on technicals at 20. A stock can carry competitive moat that high while technicals sits at 20; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 91 |
| analyst consensus | 58 |
| technicals | 20 |
StoQuant analyzes 30 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Insight Molecular Diagnostics Inc. (IMDX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/IMDX"><img src="https://stoquant.com/badge/IMDX.svg" alt="Insight Molecular Diagnostics Inc. (IMDX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.